Pia Adam, Stefan Josef Kircher, Iuliu Sbiera, Viktoria Florentine Köhler, Elke Berg, Thomas Knösel, Benjamin Sandner, Wiebke Kristin Fenske, Hendrik Bläker, Constantin Smaxwil, Andreas Zielke, Bence Sipos, Stephanie Allelein, Matthias Schott, Christine Dierks, Christine Spitzweg, Martin Faßnacht, Matthias Kroiß
- Background: Treatment options for poorly differentiated (PDTC) and anaplastic (ATC) thyroid carcinoma are unsatisfactory and prognosis is generally poor. Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine refractory thyroid carcinoma, but response to single agent is poor in ATC. Recent reports of combining LEN with PD-1 inhibitor pembrolizumab (PEM) are promising. Materials and Methods: Primary ATC (n=93) and PDTC (n=47) tissue samples diagnosed 1997-2019 at five German tertiary care centers were assessed for PD-L1 expression by immunohistochemistry using Tumor Proportion Score (TPS). FGFR 1-4 mRNA was quantified in 31 ATC and 14 PDTC with RNAscope in-situ hybridization. Normal thyroid tissue (NT) and papillary thyroid carcinoma (PTC) served as controls. Disease specific survival (DSS) was the primary outcome variable. Results: PD-L1 TPS≥50% was observed in 42% of ATC and 26% of PDTC specimens. Mean PD-L1 expression was significantly higher in ATC (TPS 30%) than in PDTC (5%; p<0.01) and NT (0%, p<0.001). 53% of PDTC samples had PD-L1 expression ≤5%. FGFR mRNA expression was generally low in all samples but combined FGFR1-4 expression was significantly higher in PDTC and ATC compared to NT (each p<0.001). No impact of PD-L1 and FGFR 1-4 expression was observed on DSS. Conclusion: High tumoral expression of PD-L1 in a large proportion of ATCs and a subgroup of PDTCs provides a rationale for immune checkpoint inhibition. FGFR expression is low thyroid tumor cells. The clinically observed synergism of PEM with LEN may be caused by immune modulation.
MetadatenAuthor: | Pia Adam, Stefan Josef KircherGND, Iuliu SbieraGND, Viktoria Florentine Köhler, Elke Berg, Thomas Knösel, Benjamin Sandner, Wiebke Kristin Fenske, Hendrik Bläker, Constantin Smaxwil, Andreas Zielke, Bence Sipos, Stephanie Allelein, Matthias Schott, Christine Dierks, Christine Spitzweg, Martin FaßnachtORCiDGND, Matthias Kroiß |
---|
URN: | urn:nbn:de:hebis:30:3-620321 |
---|
DOI: | https://doi.org/10.3389/fendo.2021.712107 |
---|
ISSN: | 1664-2392 |
---|
Parent Title (English): | Frontiers in endocrinology |
---|
Publisher: | Frontiers Research Foundation |
---|
Place of publication: | Lausanne |
---|
Document Type: | Article |
---|
Language: | English |
---|
Date of Publication (online): | 2021/08/12 |
---|
Date of first Publication: | 2021/08/12 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Contributing Corporation: | German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid Glands |
---|
Release Date: | 2022/04/25 |
---|
Tag: | FGFR; PD-L1; immune checkpoint inhibitor (ICI); immunohistochemistry; immunotherapy; tyrosine kinase inhibitor (TKI) |
---|
Volume: | 12 |
---|
Issue: | art. 712107 |
---|
Page Number: | 12 |
---|
First Page: | 1 |
---|
Last Page: | 12 |
---|
Note: | This work was supported - in part - by the Else Kröner Fresenius Stiftung, grant number 2016-A96. |
---|
HeBIS-PPN: | 494698462 |
---|
Institutes: | Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Sammlungen: | Universitätspublikationen |
---|
Licence (German): | Creative Commons - Namensnennung 4.0 |
---|